Hello, 360!
President Donald Trump claims that “The golden age of America begins right now” and that “America’s decline is over.” Regardless of your political stance, let’s hope he is right for the good of America!
Today, we invite you to join us for this special event:
FOCUS LIST🔎
HSDT – Up over 40% in pre-market after reporting strong enrollment in its stroke pivotal study, exceeding initial targets.
TEM – Up over 17% in pre-market following Nancy Pelosi’s purchase of 50 Jan 2026 $20 call options in Tempus AI on January 14.
VATE – Up over 24% in pre-market after announcing FDA approval for its MediBeacon® Transdermal GFR System for assessing kidney function.
*Sponsored by Klondike Royalties
Consider adding a piece of the energy sector to your portfolio.
-
Access to 300 million barrels of recoverable oil reserves.
-
Royalty-based investment model that reduces operational risks.
-
Projected potential royalty income for over 25 years.
Join the Raise.
HOTLIST🔥
HSDT – Up over 40% in pre-market after announcing strong enrollment of its stroke pivotal study, exceeding initial targets.
Helius Medical Technologies Inc. (HSDT) is a neurotechnology firm focused on a therapeutic neuromodulation approach for balance and gait issues.
In pre-market trading today, the company shared that it has completed and significantly exceeded the initial enrollment target for its stroke registrational program, with 128 participants randomized so far and expecting to reach the maximum enrollment of 150 by January 2025.
This stroke registrational program aims to demonstrate the safety and effectiveness of the novel Portable Neuromodulation Stimulator (PoNS®) for enhancing balance and gait in stroke survivors.
Shares of HSDT surged over 40% in pre-market trading on the news.
The $1.09 level acted as support in pre-market and will be significant to monitor.
If it holds, upward targets are $1.24, $1.30, and then the pre-market high of $1.39. Further targets include $1.45, $1.50, $1.70, and $2.
If it drops below $1.09, watch for targets to the downside at $1, $0.90, $0.85, and a gap fill at $0.7510.
TEM – Up over 17% in pre-market after Nancy Pelosi disclosed buying 50 Jan 2026 $20 call options in Tempus AI on January 14.
Tempus AI Inc (TEM) is a healthcare technology firm offering advanced sequencing diagnostics, PCR profiling, molecular genotyping, and various pathology tests to healthcare providers, research groups, and pharmaceutical companies.
This morning, it was revealed that former House Speaker Nancy Pelosi purchased 50 Jan 2026 $20 call options in Tempus AI on January 14. Given her and her husband’s impressive investment track record, the news propelled TEM shares up over 17% in pre-market trading.
The $41.39 level acted as support in pre-market and is now a potential resistance point.
If the price moves upward, targets include $42, $43, $44.50, and the pre-market high of $45.25, followed by $47 and $51.
Should it drop below $41.39, watch for downside targets at $40.59, $38.50, $37.50, $36, and a gap fill at $35.15.
VATE – Up over 24% in pre-market following FDA approval for its MediBeacon® Transdermal GFR System for kidney function assessment.
INNOVATE Corp. (VATE) operates in infrastructure, life sciences, and spectrum sectors across the United States through its subsidiaries.
On Friday evening, the company announced that the FDA has approved the MediBeacon® TGFR for assessing kidney function in patients both with and without renal impairment.
The Transdermal GFR System (TGFR) is a unique product designed for point-of-care kidney function assessment.
This methodology is intended to be effective across the adult population, not reliant on age, weight, sex, gender, race, or ethnicity.
With over 800 million individuals suffering from Chronic Kidney Disease (CKD), a leading global cause of death, the need for effective solutions has grown in the last two decades.
Following the announcement, shares of VATE increased by over 24% in pre-market trading.
The $7.20 level served as support during pre-market trading and now acts as a potential resistance level.
If the price goes higher, targets are $8, $8.20, $8.40, and the pre-market high of $8.91, with further targets of $9.56 and $10.
If it falls below $7.20, anticipate targets at $6, $5.70, and a gap fill at $5.11.
MARKET NEWS 📰
Don’t miss out on our MOBILE ALERTS! Some alerts have soared 🚀past the MOON 🌝. Text “RAGE” to 1-(888) 487-1534 📲.
DISCLAIMER: To fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application, or other service (“Services”), please review our complete disclaimer at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is solely for educational and informational purposes and should NOT be interpreted as a securities-related offer or solicitation, nor should it be relied upon as personalized investment advice. RagingBull strongly advises you to consult a licensed professional before making any investment decisions.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may include historical trading performance data of RagingBull owners or employees, and/or testimonials from non-employees depicting profitability thought to be true based on the representations of those providing the information. However, subscriber trading outcomes have NOT been tracked or verified, and past performance does not guarantee future results. The results shared in this communication are NOT TYPICAL, and actual outcomes will vary widely based on multiple factors such as experience, skill, risk management strategies, market conditions, and the amount of capital used. Investing in securities is speculative and carries a high risk; you could lose some or all of your original investment.
RAGINGBULL IS NOT A REGISTERED INVESTMENT ADVISOR OR BROKER. Neither RagingBull nor any of its owners or employees are registered as securities broker-dealers, brokers, investment advisors (IA), or IA representatives with the U.S. SEC, any state securities regulatory body, or any self-regulatory organization. Employees, owners, and other service providers at https://ragingbull.com or RagingBull.com LLC are compensated in part by commissions based on their service sales to subscribers.
RagingBull.com, LLC can recover attorneys’ fees, costs, and disbursements. If any lawsuit is initiated associated with any transactions with RagingBull.com, LLC and/or its affiliates or to enforce these Terms of Service, RagingBull.com, LLC can recover attorneys’ fees, costs, and disbursements along with any other relief sought.
*Sponsored Content: If you purchase anything via a link in this email other than RagingBull services, you should assume that an affiliate relationship exists with the product or service provider you purchased from, and that we will receive compensation. We advise you to conduct your own independent research before making any purchases. While we endorse the companies we have affiliate relationships with, only spend on these products or services if you genuinely believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been compensated directly or indirectly by any security issuer mentioned in its Services except potentially by advertisers in this email. Nevertheless, Ragingbull.com, LLC and its owners or employees may buy, sell, or hold long or short positions in the securities of the mentioned companies.
